ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Membrane-Localized HSP90 Disruption
Cell-penetrating peptides or lipid-conjugated inhibitors that specifically target HSP90 complexes at cellular membranes where tau aggregation initiates, concentrating HSP90 inhibition at sites of tau pathology while sparing cytoplasmic H.
drug discovery
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Cell-penetrating peptides or lipid-conjugated inhibitors that specifically target HSP90 complexes at cellular membranes where tau aggregation initiates, concentrating HSP90 inhibition at sites of tau pathology while sparing cytoplasmic HSP90 essential functions.
🧬 Mechanism
🔗 Mechanism from KG for HSP90AA1
Auto-built from this analysis's top knowledge-graph edges.
graph TD
HSP90AA1["HSP90AA1"] -->|participates in| protein_folding["protein_folding"]
FKBP5["FKBP5"] -->|protein interactio| HSP90AA1_1["HSP90AA1"]
FKBP4["FKBP4"] -->|protein interactio| HSP90AA1_2["HSP90AA1"]
MAPT["MAPT"] -->|regulates| HSP90AA1_3["HSP90AA1"]
HSP90AA1_4["HSP90AA1"] -->|regulates| tau_protein["tau protein"]
FKBP51["FKBP51"] -.->|inhibits| HSP90AA1_5["HSP90AA1"]
Ganetespib["Ganetespib"] -.->|inhibits| HSP90AA1_6["HSP90AA1"]
n17_AAG["17-AAG"] -.->|inhibits| HSP90AA1_7["HSP90AA1"]
HSP90AA1_8["HSP90AA1"] -->|regulates| tau_HSP90_interactions["tau-HSP90 interactions"]
Co_chaperones["Co-chaperones"] -->|modulates| HSP90AA1_function["HSP90AA1 function"]
HSP90AA1_9["HSP90AA1"] -->|regulates| proteasomal_degradation_p["proteasomal degradation pathway"]
HSP90AA1_C_terminal_domai["HSP90AA1 C-terminal domain"] -->|regulates| tau_HSP90_complex_formati["tau-HSP90 complex formation"]
style HSP90AA1 fill:#ce93d8,stroke:#333,color:#000
style protein_folding fill:#81c784,stroke:#333,color:#000
style FKBP5 fill:#ce93d8,stroke:#333,color:#000
style HSP90AA1_1 fill:#ce93d8,stroke:#333,color:#000
style FKBP4 fill:#ce93d8,stroke:#333,color:#000
style HSP90AA1_2 fill:#ce93d8,stroke:#333,color:#000
style MAPT fill:#ce93d8,stroke:#333,color:#000
style HSP90AA1_3 fill:#ce93d8,stroke:#333,color:#000
style HSP90AA1_4 fill:#4fc3f7,stroke:#333,color:#000
style tau_protein fill:#4fc3f7,stroke:#333,color:#000
style FKBP51 fill:#4fc3f7,stroke:#333,color:#000
style HSP90AA1_5 fill:#4fc3f7,stroke:#333,color:#000
style Ganetespib fill:#4fc3f7,stroke:#333,color:#000
style HSP90AA1_6 fill:#4fc3f7,stroke:#333,color:#000
style n17_AAG fill:#4fc3f7,stroke:#333,color:#000
style HSP90AA1_7 fill:#4fc3f7,stroke:#333,color:#000
style HSP90AA1_8 fill:#4fc3f7,stroke:#333,color:#000
style tau_HSP90_interactions fill:#4fc3f7,stroke:#333,color:#000
style Co_chaperones fill:#4fc3f7,stroke:#333,color:#000
style HSP90AA1_function fill:#4fc3f7,stroke:#333,color:#000
style HSP90AA1_9 fill:#4fc3f7,stroke:#333,color:#000
style proteasomal_degradation_p fill:#81c784,stroke:#333,color:#000
style HSP90AA1_C_terminal_domai fill:#4fc3f7,stroke:#333,color:#000
style tau_HSP90_complex_formati fill:#4fc3f7,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Folding or holding?-Hsp70 and Hsp90 chaperoning of misfolded proteins in neurodegenerative disease.
Supports
Hsp90-interacting Co-chaperones and their Family Proteins in Tau Regulation: Introducing a Novel Role for Cdc37L1.
Supports
The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.
Supports
To fold or not to fold: modulation and consequences of Hsp90 inhibition.
Supports
Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice.
Contradicts
Pharmacological mechanism and therapeutic efficacy of Icariside II in the treatment of acute ischemic stroke: a systematic review and network pharmacological analysis.
Contradicts
Mapping the pathogenic nexus: Gene overlap and protein interaction networks in Alzheimer's and breast cancer as a precursor to protein structure prediction and analysis.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — HSP90AA1
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for HSP90AA1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0511
Events (7d)
0
Price History
▲5.2%💾 Resource Usage
LLM Tokens
18,738
$0.1124
Total Cost
$0.1124
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we administer TAT-conjugated HSP90 membrane-binding domain peptide (10 mg/kg, i.p., daily) to 8-month-old 3xTg-AD mice for 4 weeks compared to vehicle or non-targeting TAT-scramble peptide, THEN we | ≥30% reduction in Sarkhosal-insoluble tau by ELISA; ≥40% improvement in probe trial latency (mean 25-30 sec improvement from ~45 sec baseline) | — no observation — | pending | 0.55 |
| IF we treat SH-SY5Y cells expressing P301L tau with lipid-conjugated HSP90 inhibitors (membrane-targeted) at 1 μM compared to equimolar 17-AAG (cytoplasmic HSP90 inhibitor), THEN membrane-targeted inh | ≥50% reduction in AT8 fluorescence intensity with membrane-targeted inhibitor; cytoplasmic HSP70 mRNA levels ≥80% of vehicle control | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we treat SH-SY5Y cells expressing P301L tau with lipid-conjugated HSP90 inhibitors (membrane-targeted) at 1 μM compared to equimolar 17-AAG (cytoplasmic HSP90 inhibitor), THEN membrane-targeted inhibitors will reduce phospho-tau (AT8) by ≥50% while cytoplasmic HSP70 induction (HSP90 activity read
Predicted outcome: ≥50% reduction in AT8 fluorescence intensity with membrane-targeted inhibitor; cytoplasmic HSP70 mRNA levels ≥80% of vehicle control
Falsification: Both inhibitors produce equivalent (<20% difference) reduction in AT8 signal AND equivalent (<20% difference) cytoplasmic HSP70 induction, disproving selectivity for membrane HSP90 as mechanism
pendingconf 55%
IF we administer TAT-conjugated HSP90 membrane-binding domain peptide (10 mg/kg, i.p., daily) to 8-month-old 3xTg-AD mice for 4 weeks compared to vehicle or non-targeting TAT-scramble peptide, THEN we will observe ≥30% reduction in Sarkhosal-insoluble tau aggregates in hippocampal synaptoneurosomes
Predicted outcome: ≥30% reduction in Sarkhosal-insoluble tau by ELISA; ≥40% improvement in probe trial latency (mean 25-30 sec improvement from ~45 sec baseline)
Falsification: No significant difference (p>0.05) in Sarkhosal-insoluble tau between treatment and vehicle groups, OR Morris water maze performance shows no improvement, disproving efficacy of membrane-targeted HSP9
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.